Our website uses cookies and other similar tools. We also analyze anonymized web traffic. You can choose your cookie preferences below. You may choose only necessary cookies, specific cookies or all cookies. Read more in our privacy policy
Home > All articles > Manual extraction gathered information on the drug treatment for ulcerative colitis
Manual extraction gathered information on the drug treatment for ulcerative colitis
Hospital data lakes are a central source of information in Medaffcon’s studies, and often, data retrieval can be automated. However, what happens when more complex matters need to be extracted from the databases? In such cases, manual extraction is used, says Medaffcon’s Scientific Advisor, Riikka Mattila
When data retrieval cannot be automated due to diverse sources, manual extraction provides the practical solution.
A good example of manual extraction is a Real-World Evidence (RWE)study published last fall, examining the effectiveness of treatment for ulcerative colitis. The study involved 23 Finnish IBD centers specializing in the treatment of ulcerative colitis.
According to Mattila, all the information retrieval was done manually. In each hospital, a clinical specialist extracted data from patient records manually and recorded them on a separate research form. The study sought variables describing symptoms and the severity of the disease.
“In Finland, there are four data lakes: in Helsinki, Tampere, Kuopio, and Turku. If information is needed from other hospitals, databases are not available, and the information must be retrieved manually. That’s how it was in this study,”Mattila explains.
According to Mattila, data lakes allow for the automatic extraction and mathematical analysis of numerous pieces of information, particularly when dealing with straightforward variables like hemoglobin.
“However, when collecting for example complex symptoms, they cannot be automatically extracted from the data lake. For instance, there might be a diagnosis where the doctor has included symptoms. In such cases, a person must retrieve the information,”says Mattila.
She explains that in Finland, this type of registry study is technically similar to other registry studies, even though information is retrieved from patient records. Since the study is a registry study and not a clinical trial, it does not require approval from an ethical board. The approval process is therefore lighter. “In other countries, retrieving information directly from patient records can be challenging. In Finland, such research only requires permission from Findata or the data controller. This falls under the Act on Secondary Use of Health and Social Data,”Mattila points out.
Medaffcon conducted research on the effectiveness of tofacitinib in the treatment of ulcerative colitis in collaboration with Pfizer and Finnish gastroenterologists. Mattila, along with Biostatistician Iiro Toppila and Data Scientist Olivia Hölsä, comprised the team from Medaffcon. They are part of the Data and RWE teams with a total of 15 experts.
Mattila joined Medaffcon three years ago. In her role, she primarily conducts RWE studies. She has extensive experience in various therapeutic areas, with about 15 years of research experience, including three years at the Max Planck Institute in Germany.
“What’s interesting in my current role is that I get to do science. And there’s a great atmosphere at Medaffcon,”Mattila shares.
Read more about Medaffcon’s teams and key figuresfrom 2023here.
Riikka joined Medaffcon in February 2021. She has a wide-ranging experience from different therapy areas from atherosclerosis and birth asphyxia to neurodegeneration. She has more than 15 years of experience in research, three of which in Max Planck Institute in Germany. Her PhD thesis from 2011 focused on cholesterol metabolism.
Riikka’s strenghts include broad know-how and interest in diverse therapy areas, as well as enthusiasm and experience in both written and verbal scientific communication. At Medaffcon she enjoys varied projects and effectiveness of research.
Real world evidence fascinates Riikka because there is so much data, and more accumulating all the time, and most of this data is unused. There is potential for findings to support clinicians and the pharmaceutical industry, as well as alleviate the lives of patients. She is also happy that decisions in health care are increasingly evidence based.
Iiro joined Medaffcon in March 2017 as a Biostatistician. For the preceding four years, he has worked as a research assistant in an academic study group, analyzing clinical and genetic patient data. Iiro holds a Master of Science degree in Technology in Bioinformation Technology.
Iiro’s strengths include his strong expertise in statistics and data-analysis, hands-on experience in working with sensitive patient data, and strong interdisciplinary communication skills with experts from various fields. In the field, he is particularly interested in the large data amounts made available with the revolution of technology and how the information received such data can potentially be utilized to draw concrete conclusions, both in order to understand the nature of diseases and to advance the goals of the pharmaceutical industry and patient treatment.
“Machine learning and AI-based solutions will have a major impact on the healthcare sector now and in the future. However, effectively utilizing the already collected and available health-data will have a higher importance in order to improve health-care”.
Olivia joined Medaffcon in 2021 as a trainee to work on her Master’s thesis. She is finishing her studies in bioinformatics and digital health at Aalto University and has also worked as teaching assistant alongside her studies there for three years. Her main strengths are analytical thinking, problem solving skills and proactive mindset.
She is interested in data analysis in the field of social and healthcare to support decision making in improving social and healthcare services and allocating their resources more effectively.
